RÉSUMÉ
Post-stroke depression (PSD) is a very common complication that leads to increased physical disability, poor functional outcome, and higher mortality. Therefore, early detection and treatment are very important. Since there are currently no specific guidelines for this disorder in China, the purpose of this study was to develop PSD guidelines and provide suggestions for clinicians and related workers.
Sujet(s)
Humains , Accident vasculaire cérébral/psychologie , Trouble dépressif/diagnostic , Trouble dépressif/thérapie , Psychothérapie , Facteurs temps , Indice de gravité de la maladie , Chine/épidémiologie , Facteurs de risque , Guides de bonnes pratiques cliniques comme sujet , Survivants/psychologie , Dépression/étiologie , Trouble dépressif/traitement médicamenteux , Trouble dépressif/épidémiologie , Autorapport , Réadaptation après un accident vasculaire cérébral/normes , Antidépresseurs/usage thérapeutiqueRÉSUMÉ
Post-stroke depression (PSD) is a very common complication that leads to increased physical disability, poor functional outcome, and higher mortality. Therefore, early detection and treatment are very important. Since there are currently no specific guidelines for this disorder in China, the purpose of this study was to develop PSD guidelines and provide suggestions for clinicians and related workers.
Sujet(s)
Trouble dépressif/diagnostic , Trouble dépressif/thérapie , Accident vasculaire cérébral/psychologie , Antidépresseurs/usage thérapeutique , Chine/épidémiologie , Dépression/étiologie , Trouble dépressif/traitement médicamenteux , Trouble dépressif/épidémiologie , Humains , Guides de bonnes pratiques cliniques comme sujet , Psychothérapie , Facteurs de risque , Autorapport , Indice de gravité de la maladie , Réadaptation après un accident vasculaire cérébral/normes , Survivants/psychologie , Facteurs tempsRÉSUMÉ
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in gastric/gastroesophageal junction cancer; however, the number of patients with HER2-positive disease is unclear, possibly due to differing scoring criteria/assays. Data are also lacking for early disease. We aimed to assess the HER2-positivity rate using approved testing criteria in a large, real-life multinational population. HER2-positivity was defined as an immunohistochemistry staining score of 3+, or immunohistochemistry 2+ and HER2 amplification detected by in situ hybridization. A total of 4949 patients were enrolled and results showed that 14.2% of 4920 samples with immunohistochemistry results were HER2-positive. HER2-positivity was significantly higher in males (16.1% vs. 9.6% in females), in gastroesophageal versus stomach tumors (22.1% vs. 12.9%), in biopsy versus surgical samples (18.3% vs. 13.0%), in intestinal tumor subtypes versus diffuse (21.5% vs. 4.8%) and mixed types (21.5% vs. 8.5%) (P<0.001), in mixed versus diffuse types (8.5% vs. 4.8%), and in "other" versus diffuse types (11.7% vs. 4.8%; P=0.002). There were no significant differences between stages. Patients in the youngest age percentile had significantly lower HER2-positivity rates than patients in the remaining percentiles (9.2% vs. 15.9%, 15.7%, and 15.1%; P<0.001). HER2-positivity was highest in France (20.2%) and lowest in Hong Kong (10.4%). In conclusion, HER-EAGLE, the first study of its kind to be conducted in a large, multinational population of almost 5000 patients, gives valuable insights into the real-world HER2-positivity rate in a gastric/gastroesophageal junction cancer patient population not selected for disease stage or histology.